ifosfamide + mesna + dacarbazine + etoposide

This regimen is a **combination chemotherapy protocol** composed of four drugs: **ifosfamide**, **mesna**, **dacarbazine**, and **etoposide**. - **Ifosfamide** is an alkylating agent of the oxazaphosphorine group, inducing crosslinking of DNA and inhibition of DNA synthesis and function[14][18]. - **Mesna** is not cytotoxic but acts as a uroprotectant, binding and detoxifying urotoxic metabolites of ifosfamide in the urinary tract to prevent hemorrhagic cystitis[11]. - **Etoposide** is a topoisomerase II inhibitor, causing DNA strand breaks and inhibiting replication. - **Dacarbazine** is an alkylating agent (triazene derivative), which methylates DNA and inhibits DNA synthesis and function. This specific combination is not assigned a unique trade name but represents a multi-agent regimen. It is most often utilized for **advanced or metastatic soft tissue and bone sarcomas** and refractory or relapsed solid tumors, including sarcomas, where multi-agent regimens are needed for higher response rates[1][5][6]. Ifosfamide and mesna with etoposide (sometimes in combinations without dacarbazine) are well described, but the full combination with all four components is not a widespread or standard named protocol. Notably, similar regimens such as MAID (mesna, doxorubicin, ifosfamide, dacarbazine) are standard for soft tissue sarcoma; in this query, doxorubicin is replaced by etoposide[3][6].